After more than 4,000 people in North Carolina died last year from fentanyl, a Chapel Hill company has a plan to cut down on deadly overdoses.

A Chapel Hill company is developing an injectable drug to cut down on deadly overdoses after more than 4,000 people in North Carolina died last year from fentanyl.
Fentanyl is the number one killer of Americans ages 18 to 45, with opioids producing the worst drug crisis in the history of the United States.
Chapel Hill-based Cessation Therapeutics says its monoclonal antibody therapy, called CSX-1004, can block the dangerous effects of fentanyl.
“Fentanyl can get to the brain really quickly,” said Andy Barrett, chief scientific officer for Cessation Therapeutics. “And the brain is where it produces its pleasurable effects and its dangerous respiratory depression.”
Without any intervention, fentanyl can enter the bloodstream and travel easily to the brain – but the monoclonal antibody can bind to fentanyl in the blood and prevent it from crossing that blood brain barrier.
“It would block all of the effects of fentanyl for at least a month,” Barrett said.
Continue reading “Chapel Hill company working to develop vaccine to prevent fentanyl overdoses”